This article was originally published in The Gray Sheet
Cobas Taqman and Taqman 48 analyzer Class I recall is ongoing, after the discovery that some analyzers have an "improperly seated fiber optic cable," which could falsely elevate patient hepatitis B and C virus test results. Because physicians stop or change treatment upon finding elevated test results - which show patients failing to respond to treatment - disease progression or death could result in some cases. Roche is considering redesigning the optic cable, and says its field service engineers have inspected 100 analyzers for correct cable seating. The Taqman action is a further example of an increased number of Class I recalls compared with prior years (1"The Gray Sheet" July 19, 2004, p. 16)...
You may also be interested in...
Carl Zeiss Meditec's Class I voluntary recall is part of a recent uptick in FDA announcements related to the most serious type of device recalls
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.